Beximco Pharma receives GMP approval from Health Canada
Aims to become a global generics manufacturer
Beximco Pharmaceuticals, a fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received GMP approval from Health Canada.
Beximco, based in Dhaka, is the first Bangladeshi company to receive GMP accreditation from the Canadian regulatory authority.
The company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
It employs 3,000 people and produces tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions and oral soluble films
This accreditation opens a new marketing opportunity for Beximco’s products in Canada.
At the beginning of July, Beximco also received GMP approval from the Taiwan Food & Drug Authority (TFDA), again marking a first-time approval for a Bangladeshi company.
Nazmul Hassan, Managing Director of Beximco Pharma, said: ‘Canada is an important market for Beximco Pharma and this approval marks a significant milestone for the company, further validating our high standards of quality and compliance practices.
‘This approval builds on our existing presence in key regulated markets and is an important step towards our aspiration to become a global generic drug player.’
Beximco is also certified by the European Medicines Agency (EMA) and has been exporting medicines to the EU since 2013.
The company has also received approvals from the relevant authorities in Australia, Latin America, Gulf Nations, and South Africa, among others.
